Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients
Purpose Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is a palliative therapeutic option for advanced Neuroendocrine Tumors (NETs). Prognostic factors can predict long-term outcomes and determine response to therapy. Among those already explored, biomarkers from full blood count,...
Gespeichert in:
| Veröffentlicht in: | Endocrine 2022, Vol.78 (1), p.177-185 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 185 |
|---|---|
| container_issue | 1 |
| container_start_page | 177 |
| container_title | Endocrine |
| container_volume | 78 |
| creator | de Lima, Beatriz Arruda Matheos da Silva, Rinaldo Gonçalves Carroll, Cibele Vilhena, Bruno Perez, Carolina Felix, Renata Carneiro, Michel Neto, Luiz Machado Vaisman, Fernanda Corbo, Rossana Pujatti, Priscilla Brunelli Bulzico, Daniel |
| description | Purpose
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is a palliative therapeutic option for advanced Neuroendocrine Tumors (NETs). Prognostic factors can predict long-term outcomes and determine response to therapy. Among those already explored, biomarkers from full blood count, including neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) has shown value for other solid tumors and for NETs patients submitted to other forms of therapy. However, its relation to PRRT response and patients’ prognosis is still to be determined.
Methods
Medical records from 96 patients submitted to PRRT between 2010 and 2017 were reviewed, median NLR and PLR were calculated from baseline flood blood count and dichotomized as high or low. Progression-free survival (PFS) and Overall Survival (OS) were calculated.
Results
NLR and PLR median values were 1.8 and 123, respectively. Patients with low NLR had a significantly longer OS (estimated median of 77.5 months, 95% CI: 27.3–127.7) when compared to patients with high NLR (estimated median of 47.7 months, 95% CI: 34.7–60.8);
p
= 0.04. Patients with low NLR had a trend toward a longer median PFS when compared to patients with high NLR [estimated medians of 77 months (95% CI: 27.3–127.7), and 47.7 months, (95% CI: 34.7–60.7)], respectively,
p
= 0.08.
Conclusion
Patients with advanced-stage NET with NLR higher than 1.8 have worse long term clinical outcomes after PPRT. Larger studies are needed to validate the optimal cutoff for this biomarker. |
| doi_str_mv | 10.1007/s12020-022-03133-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2689055739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2714730108</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-92cc82fd1668b2ed74e55d119deed8054046f34e07e1dc40202d61516d329fcd3</originalsourceid><addsrcrecordid>eNp9kE1PwzAMhiMEEmPwBzhF4sKl4CRNP45oGgNp2tA0zlGXuFtH15SkPezfEygSiAMnW_LzWvZDyDWDOwaQ3nvGgUMEnEcgmBCRPCEjJmUeQZif_urPyYX3ewgkT9IRWS6w75xtd1VNO0vr46HdWX3skLqiqywtPC1o6-y2sb7ydFPZQ-He0FFb0pfVak2rhi6ma9oGGpvOX5Kzsqg9Xn3XMXl9nK4nT9F8OXuePMwjLUB0Uc61znhpWJJkG44mjVFKw1huEE0GMoY4KUWMkCIzOg6_cZMwyRIjeF5qI8bkdtgbbnvv0XfqUHmNdV00aHuveJLlIGUq8oDe_EH3tndNuE7xlMWpCFqyQPGB0s5677BUravCr0fFQH06VoNjFcypL8dKhpAYQj7AzRbdz-p_Uh8lUn0w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2714730108</pqid></control><display><type>article</type><title>Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients</title><source>SpringerLink Journals</source><creator>de Lima, Beatriz Arruda Matheos ; da Silva, Rinaldo Gonçalves ; Carroll, Cibele ; Vilhena, Bruno ; Perez, Carolina ; Felix, Renata ; Carneiro, Michel ; Neto, Luiz Machado ; Vaisman, Fernanda ; Corbo, Rossana ; Pujatti, Priscilla Brunelli ; Bulzico, Daniel</creator><creatorcontrib>de Lima, Beatriz Arruda Matheos ; da Silva, Rinaldo Gonçalves ; Carroll, Cibele ; Vilhena, Bruno ; Perez, Carolina ; Felix, Renata ; Carneiro, Michel ; Neto, Luiz Machado ; Vaisman, Fernanda ; Corbo, Rossana ; Pujatti, Priscilla Brunelli ; Bulzico, Daniel</creatorcontrib><description>Purpose
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is a palliative therapeutic option for advanced Neuroendocrine Tumors (NETs). Prognostic factors can predict long-term outcomes and determine response to therapy. Among those already explored, biomarkers from full blood count, including neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) has shown value for other solid tumors and for NETs patients submitted to other forms of therapy. However, its relation to PRRT response and patients’ prognosis is still to be determined.
Methods
Medical records from 96 patients submitted to PRRT between 2010 and 2017 were reviewed, median NLR and PLR were calculated from baseline flood blood count and dichotomized as high or low. Progression-free survival (PFS) and Overall Survival (OS) were calculated.
Results
NLR and PLR median values were 1.8 and 123, respectively. Patients with low NLR had a significantly longer OS (estimated median of 77.5 months, 95% CI: 27.3–127.7) when compared to patients with high NLR (estimated median of 47.7 months, 95% CI: 34.7–60.8);
p
= 0.04. Patients with low NLR had a trend toward a longer median PFS when compared to patients with high NLR [estimated medians of 77 months (95% CI: 27.3–127.7), and 47.7 months, (95% CI: 34.7–60.7)], respectively,
p
= 0.08.
Conclusion
Patients with advanced-stage NET with NLR higher than 1.8 have worse long term clinical outcomes after PPRT. Larger studies are needed to validate the optimal cutoff for this biomarker.</description><identifier>ISSN: 1559-0100</identifier><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-022-03133-5</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomarkers ; Blood tests ; Diabetes ; Endocrinology ; Humanities and Social Sciences ; Internal Medicine ; Leukocytes (neutrophilic) ; Lymphocytes ; Medical prognosis ; Medical records ; Medicine ; Medicine & Public Health ; multidisciplinary ; Neuroendocrine tumors ; Neutrophils ; Original Article ; Patients ; Prognosis ; Radiation therapy ; Science ; Solid tumors</subject><ispartof>Endocrine, 2022, Vol.78 (1), p.177-185</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c303t-92cc82fd1668b2ed74e55d119deed8054046f34e07e1dc40202d61516d329fcd3</cites><orcidid>0000-0003-1270-7241</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12020-022-03133-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12020-022-03133-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids></links><search><creatorcontrib>de Lima, Beatriz Arruda Matheos</creatorcontrib><creatorcontrib>da Silva, Rinaldo Gonçalves</creatorcontrib><creatorcontrib>Carroll, Cibele</creatorcontrib><creatorcontrib>Vilhena, Bruno</creatorcontrib><creatorcontrib>Perez, Carolina</creatorcontrib><creatorcontrib>Felix, Renata</creatorcontrib><creatorcontrib>Carneiro, Michel</creatorcontrib><creatorcontrib>Neto, Luiz Machado</creatorcontrib><creatorcontrib>Vaisman, Fernanda</creatorcontrib><creatorcontrib>Corbo, Rossana</creatorcontrib><creatorcontrib>Pujatti, Priscilla Brunelli</creatorcontrib><creatorcontrib>Bulzico, Daniel</creatorcontrib><title>Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients</title><title>Endocrine</title><addtitle>Endocrine</addtitle><description>Purpose
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is a palliative therapeutic option for advanced Neuroendocrine Tumors (NETs). Prognostic factors can predict long-term outcomes and determine response to therapy. Among those already explored, biomarkers from full blood count, including neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) has shown value for other solid tumors and for NETs patients submitted to other forms of therapy. However, its relation to PRRT response and patients’ prognosis is still to be determined.
Methods
Medical records from 96 patients submitted to PRRT between 2010 and 2017 were reviewed, median NLR and PLR were calculated from baseline flood blood count and dichotomized as high or low. Progression-free survival (PFS) and Overall Survival (OS) were calculated.
Results
NLR and PLR median values were 1.8 and 123, respectively. Patients with low NLR had a significantly longer OS (estimated median of 77.5 months, 95% CI: 27.3–127.7) when compared to patients with high NLR (estimated median of 47.7 months, 95% CI: 34.7–60.8);
p
= 0.04. Patients with low NLR had a trend toward a longer median PFS when compared to patients with high NLR [estimated medians of 77 months (95% CI: 27.3–127.7), and 47.7 months, (95% CI: 34.7–60.7)], respectively,
p
= 0.08.
Conclusion
Patients with advanced-stage NET with NLR higher than 1.8 have worse long term clinical outcomes after PPRT. Larger studies are needed to validate the optimal cutoff for this biomarker.</description><subject>Biomarkers</subject><subject>Blood tests</subject><subject>Diabetes</subject><subject>Endocrinology</subject><subject>Humanities and Social Sciences</subject><subject>Internal Medicine</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>multidisciplinary</subject><subject>Neuroendocrine tumors</subject><subject>Neutrophils</subject><subject>Original Article</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Science</subject><subject>Solid tumors</subject><issn>1559-0100</issn><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PwzAMhiMEEmPwBzhF4sKl4CRNP45oGgNp2tA0zlGXuFtH15SkPezfEygSiAMnW_LzWvZDyDWDOwaQ3nvGgUMEnEcgmBCRPCEjJmUeQZif_urPyYX3ewgkT9IRWS6w75xtd1VNO0vr46HdWX3skLqiqywtPC1o6-y2sb7ydFPZQ-He0FFb0pfVak2rhi6ma9oGGpvOX5Kzsqg9Xn3XMXl9nK4nT9F8OXuePMwjLUB0Uc61znhpWJJkG44mjVFKw1huEE0GMoY4KUWMkCIzOg6_cZMwyRIjeF5qI8bkdtgbbnvv0XfqUHmNdV00aHuveJLlIGUq8oDe_EH3tndNuE7xlMWpCFqyQPGB0s5677BUravCr0fFQH06VoNjFcypL8dKhpAYQj7AzRbdz-p_Uh8lUn0w</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>de Lima, Beatriz Arruda Matheos</creator><creator>da Silva, Rinaldo Gonçalves</creator><creator>Carroll, Cibele</creator><creator>Vilhena, Bruno</creator><creator>Perez, Carolina</creator><creator>Felix, Renata</creator><creator>Carneiro, Michel</creator><creator>Neto, Luiz Machado</creator><creator>Vaisman, Fernanda</creator><creator>Corbo, Rossana</creator><creator>Pujatti, Priscilla Brunelli</creator><creator>Bulzico, Daniel</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1270-7241</orcidid></search><sort><creationdate>2022</creationdate><title>Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients</title><author>de Lima, Beatriz Arruda Matheos ; da Silva, Rinaldo Gonçalves ; Carroll, Cibele ; Vilhena, Bruno ; Perez, Carolina ; Felix, Renata ; Carneiro, Michel ; Neto, Luiz Machado ; Vaisman, Fernanda ; Corbo, Rossana ; Pujatti, Priscilla Brunelli ; Bulzico, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-92cc82fd1668b2ed74e55d119deed8054046f34e07e1dc40202d61516d329fcd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Blood tests</topic><topic>Diabetes</topic><topic>Endocrinology</topic><topic>Humanities and Social Sciences</topic><topic>Internal Medicine</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>multidisciplinary</topic><topic>Neuroendocrine tumors</topic><topic>Neutrophils</topic><topic>Original Article</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Science</topic><topic>Solid tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Lima, Beatriz Arruda Matheos</creatorcontrib><creatorcontrib>da Silva, Rinaldo Gonçalves</creatorcontrib><creatorcontrib>Carroll, Cibele</creatorcontrib><creatorcontrib>Vilhena, Bruno</creatorcontrib><creatorcontrib>Perez, Carolina</creatorcontrib><creatorcontrib>Felix, Renata</creatorcontrib><creatorcontrib>Carneiro, Michel</creatorcontrib><creatorcontrib>Neto, Luiz Machado</creatorcontrib><creatorcontrib>Vaisman, Fernanda</creatorcontrib><creatorcontrib>Corbo, Rossana</creatorcontrib><creatorcontrib>Pujatti, Priscilla Brunelli</creatorcontrib><creatorcontrib>Bulzico, Daniel</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Lima, Beatriz Arruda Matheos</au><au>da Silva, Rinaldo Gonçalves</au><au>Carroll, Cibele</au><au>Vilhena, Bruno</au><au>Perez, Carolina</au><au>Felix, Renata</au><au>Carneiro, Michel</au><au>Neto, Luiz Machado</au><au>Vaisman, Fernanda</au><au>Corbo, Rossana</au><au>Pujatti, Priscilla Brunelli</au><au>Bulzico, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><date>2022</date><risdate>2022</risdate><volume>78</volume><issue>1</issue><spage>177</spage><epage>185</epage><pages>177-185</pages><issn>1559-0100</issn><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>Purpose
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is a palliative therapeutic option for advanced Neuroendocrine Tumors (NETs). Prognostic factors can predict long-term outcomes and determine response to therapy. Among those already explored, biomarkers from full blood count, including neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) has shown value for other solid tumors and for NETs patients submitted to other forms of therapy. However, its relation to PRRT response and patients’ prognosis is still to be determined.
Methods
Medical records from 96 patients submitted to PRRT between 2010 and 2017 were reviewed, median NLR and PLR were calculated from baseline flood blood count and dichotomized as high or low. Progression-free survival (PFS) and Overall Survival (OS) were calculated.
Results
NLR and PLR median values were 1.8 and 123, respectively. Patients with low NLR had a significantly longer OS (estimated median of 77.5 months, 95% CI: 27.3–127.7) when compared to patients with high NLR (estimated median of 47.7 months, 95% CI: 34.7–60.8);
p
= 0.04. Patients with low NLR had a trend toward a longer median PFS when compared to patients with high NLR [estimated medians of 77 months (95% CI: 27.3–127.7), and 47.7 months, (95% CI: 34.7–60.7)], respectively,
p
= 0.08.
Conclusion
Patients with advanced-stage NET with NLR higher than 1.8 have worse long term clinical outcomes after PPRT. Larger studies are needed to validate the optimal cutoff for this biomarker.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s12020-022-03133-5</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1270-7241</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1559-0100 |
| ispartof | Endocrine, 2022, Vol.78 (1), p.177-185 |
| issn | 1559-0100 1355-008X 1559-0100 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2689055739 |
| source | SpringerLink Journals |
| subjects | Biomarkers Blood tests Diabetes Endocrinology Humanities and Social Sciences Internal Medicine Leukocytes (neutrophilic) Lymphocytes Medical prognosis Medical records Medicine Medicine & Public Health multidisciplinary Neuroendocrine tumors Neutrophils Original Article Patients Prognosis Radiation therapy Science Solid tumors |
| title | Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T00%3A57%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neutrophil%20to%20lymphocyte%20ratio%20as%20a%20prognosis%20biomarker%20of%20PRRT%20in%20NET%20patients&rft.jtitle=Endocrine&rft.au=de%20Lima,%20Beatriz%20Arruda%20Matheos&rft.date=2022&rft.volume=78&rft.issue=1&rft.spage=177&rft.epage=185&rft.pages=177-185&rft.issn=1559-0100&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-022-03133-5&rft_dat=%3Cproquest_cross%3E2714730108%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2714730108&rft_id=info:pmid/&rfr_iscdi=true |